The present invention relates to a fractionation device, used for instance for the characterization or the discrimination of nanoparticles, proteins, oligomer-protein conjugates, protein aggregates and/or polymers. The invention relates more specifically to an asymmetric flow field fractionation device.
For the last two decades, nanoparticles and recombinant proteins have been introduced in the therapeutic field. Their properties have led to the development of a variety of applications, for example targeted drug delivery, imaging agents or therapeutic activity. The use in the therapeutic field of these molecules requires additional characterization, compared to smaller molecules, in order to ensure the safety of the product. As a consequence, innovative analytical methods are required to address the specific characteristics of nanoparticles and therapeutic proteins. Especially, the size of the particles present in a sample has to be investigated thoroughly. For example, the diameter of a nanoparticle has to be less than 30 nm to prevent direct elimination by the renal system. In the case of therapeutic proteins, the formation of aggregates must be limited to avoid the occurrence of immunogenic reaction and to provide an optimal activity. As part of the analytical methodology, the separation needs to be adapted to this type of particles to provide the best sensitivity and deliver information regarding the heterogeneity of the sample.
Size Exclusion Chromatography (SEC) is commonly used for the fractionation of such particles. However, the size range applicable to SEC fractionation is restricted in the range from 1 nm to 50 nm. Moreover, a column used in SEC is dedicated to a portion of the size range. SEC then requires the use of several columns to cover the entire range. Moreover, the fractionation using SEC generates back pressures of a few tenths of bars that may induce the formation of aggregates. Finally, analytical SEC is achieved with relatively important flow rates (for instance in the range from 0.3 mL/min to 1 mL/min) that are inducing dilution effect which may lead to the disassembling of non-covalent aggregates.
For this purpose, it is known to fractionate particles using an asymmetrical flow-field flow fractionation (or separation) device (AF4).
However, the separation efficiency of analytical AF4 is significantly below the separation efficiency of SEC in the case of their common size range, due to higher band broadening effects when using AF4. Analytical AF4 consequently exhibits poor peak capacity and significantly longer analysis time than SEC, which hinders the throughput of this technique. The application of AF4 is also conditioned to more complex instrumental settings than SEC, especially to finely tune the respective flow rates of the mobile phase and the cross flow through the membrane 10. Likewise SEC, analytical AF4 requires significant flow rates (typical total flow in the fractionation channel 2 is in the range from 2 mL/min to 10 mL/min) that in concomitance with important band broadening are leading to dilution effects of the analytes or particles 12. This effect limits the particles characterization, and more specifically the protein aggregates characterization.
Finally, a typical AF4 device is generally made of several layers defining the fractionation channel 2, including a superior plate, a spacer having a cavity defining the lateral walls of the fractionation channel 2 and a membrane 10. Other layers are defining the auxiliary channel: the membrane 10 is mechanically supported by a frit 27, the frit 27 is arranged over a spacer having a cavity defining the lateral wall of the auxiliary channel 3, the spacer is arranged over an inferior plate. These layers are generally clamped, which may lead to leaks of the mobile phase when using an AF4 device.
The asymmetric flow field-flow fractionation device of the present invention has been developed to respond at least partially to the above-mentioned issues of the prior art. The asymmetric flow field-flow fractionation device is configured to separate particles dispersed in a liquid mobile phase, and includes:
The membrane being mechanically held by encapsulation in between the layers and the recess thickness being less than 100 μm, a frit is no longer needed to support the membrane. Therefore, the rigidity of the membrane at this scale, combined with its encapsulation enables to avoid the use of a frit. Moreover, the thickness of the recess is adapted to smaller total flowrates in the fractionation channel than in the prior art, reducing the pressure applied to the membrane, avoiding the membrane to rip. The thickness of the recess also avoids the diffusion of the particles 12, leading to particles 12 band broadening.
In further optional aspects of the invention, the device comprises the following features, taken individually or in any of their technically possible combinations:
Another aspect of the present invention is a system comprising an asymmetric flow field-flow fractionation device as described in an above embodiment and a detection system, wherein the sample outlet of the device is fluidically connected to the detection system, said detection system comprising at least one of an absorption spectrometer, a spectrofluorometer, a Multi Angle Light Scattering detector, a Dynamic light Scattering detector, a refractometer, a nano-electrospray ionization mass spectrometry system and a inductively coupled plasma.
In further optional aspects of the invention, the mass spectrometry system includes a fluidic channel, a layer of the device has a recess, said recess being at least partially defining the fluidic channel.
Another aspect of the present invention is a method of fabricating an asymmetric flow field-flow fractionation device configured to separate particles dispersed in a liquid mobile phase, the method including encapsulating a membrane by putting in contact face portions of two layers, at least one layer, preferably both layers being in thermoplastic elastomer, each face portion surrounding the membrane.
In further optional aspects of the invention:
Another aspect of the present invention is a method of size-based particle separation comprising injecting a sample in an asymmetric flow field-flow fractionation device, the sample comprising the particles dispersed in a liquid mobile phase and the device including:
In further optional aspects of the invention:
A “particle”, as used herein, encompasses any of analyte, nanoparticle, synthetic nanoparticle, protein, protein conjugate, protein aggregate, antibody, synthetic polymers, macromolecules, virus, cell and/or bead.
A “nanoparticle”, as used herein, is a particle which diameter is in the range from 0.5 nm to 500 nm.
A “microparticle”, as used herein, is a particle which diameter is in the range from 0.5 μm to 500 μm.
More generally, the prefix “micro”, as used herein, defines a length in the range from 0.5 μm to 500 μm.
A “sample”, as used herein, comprises particles dispersed in a liquid mobile phase.
“Focusing” particles encompasses making an initially homogenous dispersion of particles injected, subject to opposite forces, i.e. diffusion, steric effects and field-driven transport, to reach an equilibrium with a non-homogeneous distribution orthogonally to the membrane. This equilibrium may commonly be described by Fick's second law depending on particle sizes:
where c0 is the particle concentration, Uz is analyte transverse velocity, D is diffusion coefficient of particles and z=0 corresponds to the membrane wall.
Other features and advantages will also emerge from the following description, which is purely illustrative and non-exhaustive, and should be read in conjunction with the attached figures, among them:
Referring to
The device 1 includes a layer 19 being with a microfabricated recess 14 which thickness is less than 100 μm. The recess 14 defines walls of the fractionation channel 2. Another wall of the fractionation channel 2 is defined by a semipermeable membrane 10, said membrane being permeable to liquid and being configured to maintain the particles 12 in the fractionation channel 2.
The device 1 also includes an auxiliary channel 3. The auxiliary channel 3 includes an auxiliary outlet 7 (not shown in
The z position of the particles 12 schematically illustrates the particle densities in an established flow: the overall particle 12 density is the highest close to the membrane 10 in the fractionation channel 2. Moreover, the mean particle position of smaller particles 12 is higher relative to the z direction than the mean particle position of the larger particles 12.
The device 1 includes another layer 19, partially bonded to the layer 19, also being with a microfabricated recess 14, which thickness t is less than 100 μm, the recess 19 defining walls of the auxiliary channel 3. The membrane 10 is mechanically held by encapsulation in between the two layers 19 and then separates the fractionation channel 2 and the auxiliary channel 3: the membrane 10 also defines a wall of the auxiliary channel 3.
The thickness t of each recess 14 defines the thickness t the corresponding channel (fractionation channel 2 or auxiliary channel 3). The recess 14 thickness is less than 100 μm, preferably in the range from 1 μm to 100 μm and preferably in the range from 5 μm to 50 μm.
The width w of each recess can be in the range from 1 μm to 10 cm, preferably 5 μm to 1 cm and even more preferably from 10 μm to 500 μm. This width range combined with a mechanically held membrane 10 by encapsulation in between the two layers makes possible to avoid a frit in the device 1.
The semipermeable membrane is porous and therefore permeable to a liquid phase. The material of the membrane is preferably one of cellulose, mixed cellulose ester, polyvinylidene fluoride (PVDF), polyethersulfone (PES), polycarbonate. The size of the pores of the membrane 10 is preferably in the range from 0.010 μm to 1 μm. This range of pore size is for instance adapted to stop particles from proteins (of a few kDa) cells (of a few tenth of μm). A membrane 10 may be damaged by a heat treatment over 80° C.
The material of at least one of the layers 19 can be an elastomer. Therefore, it is possible to encapsulate the membrane 10 in between the layers 19, the deformation of at least a layer 19 by the membrane 10, preferably of each of the layers 19, assuring a conformable contact between the layers 19, avoiding possible leaks and/or allowing optimum pressure of the liquid mobile phase 11. Compared to clamping, which requires clamping points on both sides of the channels, encapsulation allows a uniform contact between channels, making possible to increase the channel density while reducing their width and thickness without leaks. The deformation of the elastomeric layer(s) 19 also contributes to hold mechanically the membrane 10 by a conformable contact, avoiding the need of a frit to support the membrane, and to risk to mechanically damage the membrane.
The material of the layer 19 is preferably a thermoplastic elastomer (TPE). Therefore, the layers 19 can be thermobonded and the clamping of the different layers can be avoided. The use of a thermoplastic elastomer combined with the thickness t of the recess 14 also makes possible to simplify the fabrication of an asymmetric flow field-flow fractionation device 1 by microfabricating the different layers by molding. Thus, the fabrication process of the asymmetric flow field-flow fractionation device 1 can be faster and cheaper than asymmetric flow field-flow fractionation device of the prior art.
The material of at least one of the layers 19 preferably comprises a block copolymer with a glass transition temperature Tg, Tg being less than 0° C. Preferably, each layer 19 comprises a block copolymer with a glass transition temperature Tg, Tg being less than 0° C. For example, one layer 19 can be made of ethylene and/or butylene, having a glass transition temperature Tg being less than 0° C., and another layer 19 can be made of styrene, having a glass transition temperature Tg being sensibly 100° C. Therefore, the bonding between the layers 19 is achieved only by bringing the two layers 19 in contact at a temperature being less than 100° C., preferably in the range from 0° C. and 100° C. and more preferably in the range from 50° C. and 100° C., even more preferably in the range from 75° C. and 85° C. Preferably, Tg is less than −30° C. and even more preferably, Tg is less than −50° C.
A face 18 of a layer 19 is not perfectly smooth. Then, the material of the layer 19 has to be enough flexible so that two faces 18 of different layers 19 have enough surface in contact to be thermobonded. Preferably, the Young modulus of the material of at least one of the layers 19 is less than 10 MPa, and more preferably less than 2 MPa, and even more preferably comprised between 1.2 MPa and 1.3 MPa. Therefore, the material is flexible enough to allow for thermobonding of the layer 19. Therefore, two layers 19 can be thermobonded to encapsulate a membrane 10 without setting a heat treatment that may damage the membrane 10: the temperature can be for example less than 80° C., preferably less than 50° C., and more preferably less than 30° C.
The material of a layer 19 can be selected from the group consisting of polystyrène-b-polybutadiène-b-polystyrène (SBS), polystyrène-b-polyisoprène-b-polystyrène (SIS), polystyrène-b-poly(éthylène-butylène)-b-polystyrène (SEBS), polystyrène-b-poly(éthylène-propylène)-b-polystyrène (SEPS), polystyrène-b-poly(éthylène-étylène/propylène)-b-polystyrène (SEEPS), Flexdym.
Referring to
Referring to
Referring to
Referring to
Referring to
Referring to
A manifold can be produced using CNC machining on a hard translucent polymer material (PC, PMMA and/or baked epoxy) or 3D printing. The manifold can present standard chromatography female fitting (UNF 1/4-28) or luer taper.
The conduct can also comprise a stud. A stud is for example glued (using Norland Optical Adhesive NOA) or thermally bonded on layer 19 top face portion depending on stud material (PDMS or Flexdym). For PDMS, we apply NOA on the stud contact surface. Then, in contact with the layer 19, a UV beam generated from a UV curing pointer (UTarget from Black Hole Lab) is applied for 30 seconds on the NOA. When using Flexdym as the layer 19 material, thermal bonding at 140° C. for 20 s) of the stud on layer 19 is achieved before encapsulating the membrane. The 1/16 inch tube is held tight in the stud 1 mm hole. Tubing is typically used for providing the sample 8 to the conduct or directly to the fractionation channel 2. The inner diameter of the tube can be in the range from 50 μm to 1000 μm, more preferably from 100 μm to 250 μm.
The asymmetric flow field-flow fractionation device 1 comprises a sample outlet 6. The sample outlet 6 connects the fractionation channel 2 to a channel or a conduct. The conduct can include a luer connection.
The auxiliary channel 3 includes an auxiliary outlet 7. The auxiliary outlet 7 connects the auxiliary channel 3 to a channel or a conduct. The fractionation channel 2 and the auxiliary channel 3 may not be entirely superimposed (i.e. they may be superimposed only along a portion of each of the channel). Therefore, the fluidic connections to the different flow outlets can be separated.
The asymmetric flow field-flow fractionation device 1 includes two layers 19 and a membrane 10 forming a fractionation channel 2 superimposed to an auxiliary channel 3 as described above. The layers 19 can be mechanically held by a substrate (not shown), which can be made of any rigid material, as glass for example.
Referring to
Because of the possible direct encapsulation of the membrane by the layers 19, the design of the membrane can be different than the design of the fractionation channel 2 and/or than the design of the auxiliary channel 3. For example, the membrane can cover the surface covered by the serpentine shaped channels. In
In another aspect of the invention, the device can also include parallel fractionation channels 2 (not shown), i.e. the sample inlet 5 can be fluidically connected to a plurality of fractionation channels 2. Therefore, multiple separations can be performed at the same time, enabling to correct the error made in a single separation measurement.
Referring to
The mobile phase inlet 4 also allows the focusing the sample 8 upstream the fractionation channel 2. Indeed, focusing the particles 12 in the z direction and/or in x direction allows for a sharper separation of the particles 12 in the fractionation channel 2.
The asymmetric flow field-flow fractionation device 1 also comprises a separation zone 22, where the fractionation channel 2 and the auxiliary channel 3 are superimposed and separated by the membrane 10. The particles 12 are separated by their size in the separation zone 22, as described above.
The device can also comprise an output zone 23, comprising the sample outlet and the auxiliary outlet 7.
Referring to
In reference to
In reference to
The device 1 can be used to fractionate particles 12 from a sample 8, in order to collect new samples comprising particles having a monodispersed size distribution, compared to the size distribution of the particles 12 of the sample 8 injected in the device 1.
Referring to
The detection system 26 can be at least one of an absorption spectrometer, for example a UV, a visible absorption spectrometer, a spectrofluorometer, a particle light scattering detector, for example a Multi Angle Light Scattering detector and/or a Dynamic light Scattering detector, a refractometer, for example a differential refractometer, a mass spectrometry system, for example a nano-electrospray ionization mass spectrometry system, a inductively coupled plasma, a liquid chromatography detector and a electrochemical detector.
Due to miniaturization constraints, in particular sample overloading, the quantity of sample 8 injected in the device is reduced. Therefore, the system 15 requires preferably a detection system 26 having a low limit of detection, preferably less than 10 ppm, more preferably less than 1 ppm. Therefore, the detection system 26 preferably comprises a nano-electrospray ionization mass spectrometry (MS) system, which detection limit is around 0.1 ppm. Moreover, the nano-electrospray ionization mass spectrometry system is adapted to detect particles in a range of flowrate overlapping the range of flowrate in the fractionation channel 2, for example from 70 μL/min to 500 μL/min.
In a preferred aspect of the invention, an on-chip mass spectrometer or an electrochemical detector can be fabricated at least partially in the same microfluidic chip than the asymmetric flow field-flow fractionation device 1. Particularly, the detection system 26 can comprise at least a detection channel defined by a recess in a layer 19.
Another aspect of the invention is a method 130 of size-based particle separation comprising injecting the sample 8 into a device 1.
In reference to
In a preferred embodiment, the method 130 is a method of analyzing the sample 8 composition in particles 12. The method 130 can comprise a step 132 of analyzing the sample composition in particles 12. Preferably, analyzing the sample composition in particles 12 can be performed by sequentially detecting the mean quantity of particles 12 flowing through a detection volume in the fractionation microchannel 2 and/or from the outlet of the fractionation microchannel 2. In an aspect of the invention, the sample outlet 6 can be fluidically connected to a detection system 26. The detection system 26 can sequentially detect the mean quantity of particles flowing through a detection volume in a fluidic channel of the particle detector 26. Therefore, the quantities of each size-separated population of particles 12 can be detected as different peaks. The detection system 26 can optionally measure the composition of the sample directly by measuring the particles 12 quantity in the fractionation channel 2, i.e. on-chip.
In reference to
The sample 8 and the liquid mobile phase 11 can also be injected separately to the fractionation channel 2 respectively by the sample inlet 5 and by the mobile phase inlet 4. Therefore, the sequence of sample 8 and mobile phase 11 introduced in the fractionation channel 2 can be controlled by actuating a flowrate controller of sample 8 and a flowrate controller of liquid mobile phase 11. The injection flow rate of the liquid mobile phase 11 is preferably in the range from 70 nL/min to 1 mL/min, and preferably in the range from 70 μL/min to 500 μL/min.
Injecting a liquid mobile phase 11 in a step 133 also allows for focusing the sample 8 in the fractionation channel 2. The liquid mobile phase 11 is then injected while injecting sample 8 in the device 1, i.e. step 131 and step 132 can be performed in the same time. Indeed, typical junction configuration for focusing can be arranged upstream the fractionation channel 2. For example, the liquid mobile phase 11 can be injected in the mobile phase inlet 4, preferably at a flowrate in the range of 70 nL/min to 1 mL/min and preferably in the range from 70 μL/min to 500 μL/min. The liquid mobile phase 11 can permeate into the fractionation channel 2 through the inlet frit 28. The liquid mobile phase 11 flow meets the sample 8 flow coming from the sample inlet 5, and compresses the sample toward the membrane 10 wall, achieving hydrodynamic relaxation for 30 s, preferably 1 s and more preferably 10 ms.
In reference to
The above-mentioned device 1 and method 130 can be particularly used for separating and analyzing the composition of a sample 8 comprising proteins and protein aggregates. Therefore, the analysis of a sample 8 comprising both proteins and protein aggregates is possible while limiting the aggregation of proteins induced by the separation technique, as the separation is possible with a pressure of the liquid phases in the device 1 being less than 8 bars, preferably less than 3 bars. Particularly, the sample 8 can comprise therapeutic proteins, as conjugated albumin and/or monoclonal antibodies. Therefore, the stability of the proteins of a sample 8 can be evaluated by analyzing of the composition of the sample 8 by the method 130 and particularly by computing the ratio of proteins versus protein aggregates. The device can also detect and analyze the quantity of predetermined proteins and the quantity of aggregates of said proteins from therapeutic protein preparations, stability samples or eventually a patient sample, simplifying the follow-up of patients.
The size and quantity of synthetic particles 12, as nanoparticles for instance, can also be characterized utilizing the device 1. Preferably, the sample 8 can include synthetic liposomes.
Number | Date | Country | Kind |
---|---|---|---|
18305185.3 | Feb 2018 | EP | regional |
Filing Document | Filing Date | Country | Kind |
---|---|---|---|
PCT/EP2019/054365 | 2/21/2019 | WO | 00 |